Home » Newsletters » BioWorld Science

BioWorld Science

June 28, 2002

View Archived Issues

FeRx and NCCRI of Japan collaborate on gene therapy research

IntegraGen identifies location of three genes linked to early onset of obesity

Geron refocuses development pipeline

Phase III program initiated for Actiza

Fibrostat efficacy and safety in scarring confirmed in phase II trial

SLE clinical development candidate selected at Active Biotech

Noninvasive radiopharmaceutical detects infection/inflammation in 100% of patients

Sigma-Tau patents antitumor and chemosensitizing compounds

Novel 5-HT6 antagonists and their use in cognition disorders

Fujisawa claims beta3-adrenoceptor agonists for urinary incontinence, etc.

New use of Apomate discussed at SNM meeting

Amrad presents cannabinoid modulators with potential in the treatment of pain

New MEK inhibitors in early development at AstraZeneca

Anticonvulsant alkynyl amides synthesized by Abbott researchers

Cholesterol-lowering lanosterol synthase inhibitors identified at Roche

Testosterone bioadhesive buccal tablet is an attractive alternative for hypogonadism

Celgene expands Revimid development program

Amylin initiates phase II study of AC-2993 LAR

E.U. approval obtained for Tamiflu

Scynexis and Merck collaborate on antiinfective drug discovery

FR-167653 suppresses cytokine levels and exerts cardioprotective effects in rat model of CHF

Study to evaluate Diachrome's ability to improve carbohydrate metabolism in type 2 diabetics

Results of Aryplase extension study in MPS VI

Neuronyx and Centocor collaborate on stem cell-based cardiovascular therapies

131I-TM-601 receives orphan drug status in U.S.

Guanylyl cyclase C-specific ligand selectively images colon cancer and metastases

Corixa granted appeal for Bexxar

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 10, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 10, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Brenig Therapeutics discovers new LRRK2 inhibitors
BioWorld Science
Brenig Therapeutics Inc. has described leucine-rich repeat kinase 2 (LRRK2; dardarin) and (LRRK2; dardarin) (G2019S mutant) inhibitors reported to be useful for...